Background: As an important link in the process of medical reform, the drug reimbursement system has attracted widespread attention, and scientific and transparent drug reimbursement catalog and policies are particularly important. MCDA is a decision analysis that focuses on selection among conflicting and incommensurable schemes. The process includes clarifying the target technology to be evaluated, clarifying decision criteria and their weights, and evaluating and optimizing the target technology based on decision criteria. In recent years, due to the limitations of traditional health decision-making methods, more and more researchers and policymakers have applied MCDA to policy making. It is necessary to analyze the application of MCDA in drug reimbursement through systematic evaluation, and make drug reimbursement decisions based on fragmented evidence.
Objective: To systematically evaluate and analyze the application of MCDA in drug reimbursement, and provide methodological support for drug reimbursement decision-making in China.
Methods: Using synonyms of "MCDA" and "drug reimbursement" as search strategy. We systematically searched Web of Science、PubMed、EBSCO、CNKI and other databases to identify all potential studies, without restriction of search date and language. All included studies were selected manually and coded by two independent reviewers and any objection would consulted by a third reviewer. After literature screening, the included literature will show the results through the method of systematic review.
Results: This study is ongoing.
Conclusion: The contradiction between the limited reimbursement fund and people's demand for drug reimbursement continues to exist, requiring policymakers to formulate more scientific and reasonable medical insurance policies as soon as possible.